Mesoblast Limited (ASX:MSB)
Australia · Delayed Price · Currency is AUD 2.910
+0.110 (3.93%)
At close: Dec 19, 2025
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
323.85K AUD
Profits / Employee
-1.92M AUD
Market Cap
3.73B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ramsay Health Care | 90,000 |
| Sonic Healthcare | 45,000 |
| CSL Limited | 29,904 |
| Ansell | 15,000 |
| Regis Healthcare | 12,000 |
| Cochlear | 5,500 |
| Telix Pharmaceuticals | 234 |
| Pro Medicus | 132 |
Mesoblast News
- 9 days ago - Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD - GlobeNewsWire
- 17 days ago - Mesoblast Participation at Piper Sandler Conference - GlobeNewsWire
- 25 days ago - This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
- 25 days ago - Analyst Upgrade for Mesoblast (MESO): Jefferies Lifts Rating to Buy | MESO Stock News - GuruFocus
- 25 days ago - Mesoblast Sees Continued Ryoncil Revenue Growth For Q4 2025 - Nasdaq
- 26 days ago - Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue - GlobeNewsWire
- 4 weeks ago - MESO: Mesoblast Announces Pivotal Trial Collaboration for Ryoncil in Severe aGvHD - GuruFocus
- 4 weeks ago - Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids - GlobeNewsWire